Novartis CEO warns that data on Covid-19 drugs is missing
Business was good for Novartis in the first quarter of the year.
Keystone / Georgios Kefalas
Potential pharmaceutical solutions to combat Covid-19 must have strong clinical data to back their efficacy, according to Novartis boss Vasant Narasimhan.
This content was published on
2 minutes
SDA-Keystone/ac
Español
es
Novartis: faltan datos sobre fármacos anticoronavirus
Clinical studies that are properly conducted are necessary to really determine the benefit of drugs, Narasimhan told the Reuters news agency on Tuesday. Only a few drugs had met the standards so far, he said.
The Swiss pharmaceutical company has initiated a clinical study with the anti-malarial drug hydroxychloroquine. Last month he told the Swiss media that pre-clinical studies in animals as well as the first data from clinical studies showed that hydroxychloroquine kills the coronavirus. While the therapy is not yet available, Narasimhan hinted that the first study results could be available in summer.
The Basel-based company also announced its first quarter results on Tuesday, reporting a 11% increase in net sales and a turnover of $12.28 billion (CHF12 billion). Novartis says it has managed to weather the coronavirus storm to keep production facilities going.
“Our operations and product demand remain very stable and strong. Mitigating actions helped to ensure minimal disruption to supply chain and ability to meet forward purchasing demand,” according to a company statement.
Forward purchasing and lower spending meant that Novartis made an extra $400 million due to the coronavirus pandemic in the first quarter. However, it is likely that these gains will be reversed over the remainder of 2020, the company cautioned.
More
More
Swiss hospitals launch drug trial to prevent Covid-19 infection
This content was published on
Researchers in Geneva and Basel have launched a clinical trial to test two drugs on people that have been in contact with Covid-19 patients.
Registration opens for Eurovision Song Contest 2025 tickets
This content was published on
Registration for tickets to watch the Eurovision Song Contest 2025, which will be held in the Swiss city of Basel in May 12-17, opened on Monday.
Swiss Federal Railways’ new timetable passes ‘commuter test’
This content was published on
The changeover to a new Federal Railways timetable went smoothly for Swiss commuters on Monday morning. Trains were punctual and no overcrowding was observed, say officials.
Nestlé Waters faces Perrier production stoppage, French media report
This content was published on
Nestlé Waters faces a possible halt to its production of Perrier mineral water in the south of France due to health risks, according to French news reports.
Number of Swiss residents claiming benefits drops again
This content was published on
A total of 249,700 people claimed some form of welfare in Switzerland in 2023, representing a social assistance rate of 2.8% - a level not seen since 2005.
This content was published on
Wood is hardly ever recycled in Switzerland. A study by the Swiss Federal Laboratories for Materials Science and Technology (Empa) shows the recycling rate for wood is just under 8%.
Swiss union criticizes ‘insufficient’ wage increases
This content was published on
The Swiss union organisation Travail.Suisse has given a mixed view on 2025 wage negotiations. It says wage increases in some sectors are insufficient to offset the decline in purchasing power.
Ex-Syrian vice-president Rifaat al-Assad could avoid trial in Switzerland
This content was published on
The case against Rifaat al-Assad, the uncle of ousted President Bashar al-Assad who is due to be tried by the Swiss Federal Criminal Court for war crimes and crimes against humanity, could be dropped.
Survey: 82% of Swiss want to ban mobile phones in schools
This content was published on
The vast majority of Swiss residents (82%) want to ban mobile phones in schools, according to a survey published on Sunday. Even young people support the measure.
Swiss Re boss warns of ‘trust deficit’ after killing of UnitedHealth CEO
This content was published on
The murder of UnitedHealth Group executive Brian Thompson in the US and sympathy for the crime are worrying signs for insurers, according to Swiss Re CEO Andreas Berger.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
‘Anti-malaria drug can kill coronavirus’: Novartis chief
This content was published on
Swiss pharmaceutical giant Novartis believes the anti-malaria drug hydroxychloroquine offers one of the best hopes to combat coronavirus.
WHO and Roche launch trials of potential coronavirus treatments
This content was published on
Roche is launching a clinical trial of a potential new Covid-19 drug, adding to rapidly growing investments in combating coronavirus.
Balancing hope and science in the search for a coronavirus cure
This content was published on
The debate surrounding the antimalarial drug hydroxychloroquine epitomises companies' balancing act between hope and scientific realities.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.